Deadline Approaching in Lawsuit for MacroGenics, Inc. (NASDAQ: MGNX) Shareholders – Contact Shareholders Foundation for Information

Investors in MacroGenics, Inc. (NASDAQ: MGNX) are facing a looming deadline in a lawsuit that was filed for certain shareholders who purchased shares of the company. The deadline, set for September 24, 2024, is fast approaching, and investors are urged to take action.

The lawsuit stems from allegations of material misrepresentations made by MacroGenics, Inc. regarding the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine. The study, which investigated the drug package “Vobra Duo,” revealed concerning safety and efficacy data, including a high adverse event rate and several deaths linked to the study.

Analysts have expressed surprise and dismay at the changes in Vobra Duo’s safety profile and have questioned management’s transparency in disclosing this information to investors. As a result, an investor in NASDAQ: MGNX shares filed a lawsuit against MacroGenics, Inc. on July 26, 2024, alleging violations of securities laws.

Investors who purchased shares of MacroGenics, Inc. in excess of $100,000 between October 7, 2020, and March 19, 2024, have certain options and should contact the Shareholders Foundation, Inc. at mail@shareholdersfoundation.com or call +1(858) 779 – 1554. The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and settlement claim filing service that provides information related to shareholder issues and securities class actions.

With the deadline for the lawsuit approaching, investors are advised to stay informed and take necessary action to protect their investments in MacroGenics, Inc. (NASDAQ: MGNX).